# A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions

> **NCT05347576** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 31 (actual)

## Conditions studied

- Type2Diabetes

## Interventions

- **DRUG:** CKD-393(2)
- **DRUG:** CKD-501, D759, D150, D029

## Key facts

- **NCT ID:** NCT05347576
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-21
- **Primary completion:** 2022-05-02
- **Final completion:** 2022-05-09
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05347576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05347576, "A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05347576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*